ReviewInternational journal of hematology-oncology and stem cell research2017
Cytogenetic Abnormalities in Myelodysplastic Syndromes: An Overview.
Review in International journal of hematology-oncology and stem cell research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Deletion 11q, monosomy 13, and deletion 13q in noncomplex karyotype acute myeloid leukemia.Blood neoplasia · 2026Article
- Isolated Neutropenia as a Sentinel of High-Risk Clonal Evolution: Acute Myeloid Leukemia With Myelodysplasia-Related Changes HarboringJournal of medical cases · 2026Article
- Novel Approaches to the Management of Myelodysplastic Syndromes: The Roles of Artificial Intelligence and Oxidative Stress Biomarkers.Hematology reports · 2026Review
- Impact of Pre-Treatment Serum Ferritin on Response and Survival in Myelodysplastic Syndromes Treated With Azacytidine: A Multivariate Analysis.Cancer medicine · 2025Article
- Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome.International journal of molecular sciences · 2024Review
- Cytogenetic profile and risk of transformation to acute myeloid leukemia (AML) in Indonesian patients with myelodysplastic syndrome (MDS): a pilot study.F1000Research · 2024Article
- Predicted leukocyte telomere length and risk of myeloid neoplasms.Human molecular genetics · 2023Article
- Usefulness of New Neutrophil-Related Hematologic Parameters in Patients with Myelodysplastic Syndrome.Cancers · 2023Article
- The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw.Cancers · 2023Review
- Myelodysplastic Syndrome: Diagnosis and Screening.Diagnostics (Basel, Switzerland) · 2022Review
- Mutation in SF3B1 gene promotes formation of polyploid giant cells in Leukemia cells.Medical oncology (Northwood, London, England) · 2022Article
- TIRAP drives myelosuppression through an Ifnγ-Hmgb1 axis that disrupts the endothelial niche in mice.The Journal of experimental medicine · 2022Article
- Effect of 5-Azacitidine Treatment on Redox Status and Inflammatory Condition in MDS Patients.Antioxidants (Basel, Switzerland) · 2022Article
- Cytogenetic characteristics in Vietnamese patients diagnosed with primary myelodysplastic syndromes.Leukemia research reports · 2022Article
- Article
- Genome-wide cell-free DNA screening: a focus on copy-number variants.Genetics in medicine : official journal of the American College of Medical Genetics · 2021Article
- Bioenergetic Profiling of the Differentiating Human MDS Myeloid Lineage with Low and High Bone Marrow Blast Counts.Cancers · 2020Article
- Review
- Review
- Pure Red Cell Aplasia with Del(20q) Sensitive for Immunosuppressive Treatment.Case reports in hematology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Karyotype is one of the main constituents of the International Prognostic Scoring System (IPSS) and revised-IPSS that are the cornerstones for the prognostication of patients with myelodysplastic syndromes (MDS). Del(5q), -7/del(7q), +8 and -Y are among the most extensively studied cytogenetic abnormalities in MDS. The same applies for normal karyotype. There are hundreds of other rare cytogenetic abnormalities that have been reported in MDS, included but not limited to -X, 3q abnormalities, +13/del(13q), i(17q), +21/-21. However, due to a very low number of patients, their impact on the prognosis of MDS is limited. Knowledge of the molecular consequences of different cytogenetic abnormalities allows us to modify treatment regimens based on drugs most active against the specific karyotype present, allowing for the opportunity to individualize MDS treatment and improve patient care and prognosis.
Indexed as
Identifiers
28989590PMC5625474What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.